Table 3 The treatments and outcomes of patients
Case A | Case B | Case C | Case D | Case E | ||
|---|---|---|---|---|---|---|
Treatment for COVID‐19 | Antipyretic | None | Ibuprofen | Ibuprofen | Ibuprofen | None |
Antibiotic | None | Meropenem | Cefdinir | Meropenem | Cefixime → Cefoperazone and Sulbactam | |
Immunosuppression treatment | Pre-COVID‐19 | CsA 80 mg bid + PA 7.5 mg qd + MMF 0.5 g bid | CsA 40 mg bid + MMF 0.25 mg qd | TAC 2.5 mg bid | TAC 2.5 mg bid | CsA 0.15 mg |
During COVID‐19 | Extenuate MMF first, then PA, finally to CsA 45 mg bid | CsA 30 mg bid | Extenuate TAC three times to 1.0 mg-1.5 mg | Stop all the immunosuppressant | Stop all the immunosuppressant | |
At discharge | CsA 45 mg bid | CsA 30 mg bid + MMF 0.25 mg qd | TAC 1.0 mg-1.5 mg bid | TAC 2.5 mg bid | none | |
At the latest follow-up | CsA 60 mg bid | CsA 30 mg bid | TAC 2.0 mg-1.5 mg | TAC 2.5 mg bid | CsA 0.15 mg | |
Hospitalization | Times | 2 | 1 | 1 | 1 | 1 |
Total duration (day) | 46 | 0 | 21 | 27 | 19 | |
COVID-19 outcome | Cured | Cured | Cured | Cured | Cured | |
Follow‐up duration after the diagnosis of SARS-CoV-2 infection (day) | 213 | 228 | 203 | 140 | 167 | |
COVID-19 sequelae or reinfection | None | None | None | None | None | |
Blood test at the latest follow-up | WBC3.5–9.5 × 10^9/L | 11.77↑ | 8.9 | 2.4 | 10.91 | 9.73 |
Lymphocytes (#)1.2–3.4 × 10^9/L | 4.29↑ | 3.52↑ | 25.1 | 1.64 | 4.16↑ | |
CRP0-8 mg/L | < 0.5 | < 0.5 | < 0.5 | < 0.5 | < 0.5 | |
ALT9-50 IU/L | 31 | 46 | 24 | 16 | 40 | |
AST15-40 U/L | 44↑ | 64 | 22 | 38 | 67 | |
γ-GT10-60 U/L | 42 | 16 | 19 | 9 | 16 | |
Newly-onset LT complication | None | None | None | None | None |